MI-MarketIntelligence (Premium-2): How to Stop Bone Loss After Denosumab? No Easy Answers

Patients who discontinue treatment with the osteoporosis drug denosumab, despite transitioning to zoledronate, show significant losses in lumbar spine bone mineral density (BMD) within a year, according to the latest findings to show that the rapid rebound of bone loss after denosumab discontinuation is not easily prevented with other therapies — even bisphosphonates.

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

Osteoporosis
The study will evaluate the impact of Henlius' candidate on bone mineral density. • Source: Shutterstock

“When initiating denosumab for osteoporosis treatment, it is recommended to engage in thorough shared decision-making with the patient to ensure they understand the potential risks associated with discontinuing the medication,” senior author Shau-Huai Fu, MD, PhD, Department of Orthopedics, National Taiwan University Hospital Yunlin Branch, Douliu, Taiwan, told Medscape Medical News.

Shau-Huai Fu, MD, PhD,

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Market Intelligence

US Original PMAs and Panel-Track Supplementss

 
• By 

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

MI-MarketIntelligence (Premium-2): How to Stop Bone Loss After Denosumab? No Easy Answers

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

[Test]US Original PMAs and Panel-Track Supplements

 
• By 

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

More from Data Trackers

US PMA Supplements

PMA supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

Mergers and Acquisitions

Mergers and acquisitions in the medical device, diagnostics and digital health sectors. Data derived from Citeline’s Meddevicetracker.

Non-US Approvals

Devices authorized for marketing outside the US. Data derived from Citeline’s Meddevicetracker. Updated weekly.